Found 5 articles for: "Imiquimod"
Medical and Surgical Management of Multifocal Superficial Basal Cell Carcinoma
May 2025 | Volume 24 | Issue 5 | Original Article | 483 | Copyright © May 2025
Background: Multifocal superficial basal cell carcinoma (sBCC) is a subtype of BCC characterized by subclinical extension of noncontiguous tumor islands and high recurrence rates...
Read MoreSynergistic Mechanisms of 5-Fluorouracil and Imiquimod in the Treatment of Actinic Keratoses
May 2025 | Volume 24 | Issue 5 | Editorials | e35 | Copyright © May 2025
Citation: Regester RM, Cannella AC, Thiele GM, et al. Synergistic mechanisms of 5-fluorouracil and imiquimod in the treatment of actinic keratoses. J Drugs Dermatol. 2025;24(5):e35....
Read MoreKeratinocyte Carcinoma Chemoprevention With a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin
May 2023 | Volume 22 | Issue 5 | Original Article | 486 | Copyright © May 2023
Background: The incidence of keratinocyte carcinomas (KCs), comprising basal and squamous cell carcinomas, is rising in the United States. Chemoprevention is one modality by whic...
Read MoreAssessing the Efficacy of Imiquimod Use in Patients With Persistent Locally Advanced Melanoma In Situ
May 2023 | Volume 22 | Issue 5 | Original Article | 457 | Copyright © May 2023
Background: The standard of care when treating melanoma in situ (MMIS) is an excision with at least 5 mm surgical margins.1 Some studies have suggested up to 9 mm margins to maxi...
Read MoreA Non-Surgical and Cost-Effective Treatment Approach Employing Topical Imiquimod, 5-Fluorouracil, and Tretinoin for Primary Non-Melanoma Skin Cancers
March 2021 | Volume 20 | Issue 3 | Original Article | 260 | Copyright © March 2021
Background: Minimally invasive alternative approaches to treat non-melanoma skin cancers remain limited and unproven.
Objective: We aim to assess the efficacy o...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.